J. Keith Joung

J. Keith Joung is a Professor of Pathology at Harvard Medical School. He also serves as the Associate Chief of Pathology at Massachusetts General Hospital.[1]

Education

Joung received his A.B. in the Biochemical Sciences from Harvard University in 1987, his M.D. from Harvard Medical School in 1996, and his Ph.D. from Harvard University in 1996. He completed his post-doctoral fellowship with Carl Pabo at the Massachusetts Institute of Technology and the Howard Hughes Medical Institute.

Career

Joung is well-regarded as a longstanding leader in the genome editing field and has contributed to the development of designer nucleases through protein engineering and detection of off-targets. He was the Founder of the Zinc Finger Consortium in the mid-2000s.[2] More recently, he worked on the development of the TAL effector nucleases and the RNA-guided CRISPR/Cas9 system.

He was the first to demonstrate the use of the CRISPR/Cas9 system in vivo through the zebrafish model [3] and invented GUIDE-Seq to detect off-target effects in an unbiased manner.[4]

References

  1. ↑ "Joung Laboratory - Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 2016-11-19.
  2. ↑ "The Zinc Finger Consortium | Consortium Members". zincfingers.org. Retrieved 2016-11-19.
  3. ↑ Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR*, Joung JK*. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013 Mar;31(3):227-9.
  4. ↑ Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2015)


This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.